PDF Cover

Small Interfering RNA Therapeutics Market

The market for Small Interfering RNA Therapeutics was estimated at $1.3 billion in 2024; it is anticipated to increase to $3.5 billion by 2030, with projections indicating growth to around $8.1 billion by 2035.

Report ID:DS1804094
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Biotechnology
Small Interfering RNA Therapeutics
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Small Interfering RNA Therapeutics Market Outlook

Revenue, 2024

$1.3B

Forecast, 2034

$6.9B

CAGR, 2025 - 2034

18.2%

The Small Interfering RNA Therapeutics industry revenue is expected to be around $1.5 billion in 2025 and expected to showcase growth with 18.2% CAGR between 2025 and 2034. The market for Small Interfering RNA Therapeutics has expanded substantially because of various key factors. The main factor behind this growth is the rising number of genetic disorders and chronic diseases worldwide which requires new therapeutic approaches. The medical field has experienced a revolution through RNA interference technology which includes Small Interfering RNA Therapeutics because these treatments provide precise and efficient and minimally invasive therapeutic solutions. The market growth benefits from both ongoing biotechnology progress and increasing research and development funding. The medical field continues to value Small Interfering RNA Therapeutics because these treatments can specifically target genes that contribute to disease progression.

Small Interfering RNA Therapeutics, also known as siRNA Therapeutics, functions as a drug class which utilizes RNA interference mechanisms to block disease-causing gene expression. The therapeutic method shows specificity because it targets only the genes of interest which minimizes potential side effects. Small Interfering RNA Therapeutics serves multiple therapeutic purposes including cancer treatment and genetic disorder management and viral infection management.

Small Interfering RNA Therapeutics market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Small Interfering RNA Therapeutics Market Outlook

Market Key Insights

  • The Small Interfering Rna Therapeutics market is projected to grow from $1.3 billion in 2024 to $6.9 billion in 2034. This represents a CAGR of 18.2%, reflecting rising demand across Oncology Therapeutics, Genetic Disorders Treatment, and Viral Infections Management.

  • Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Small Interfering Rna Therapeutics market and are expected to observe the growth CAGR of 17.5% to 25.5% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Malaysia are expected to observe highest growth with CAGR ranging between 13.6% to 18.9%.

  • Transition like Advancements in Drug Delivery Systems is expected to add $212 million to the Small Interfering Rna Therapeutics market growth by 2030

    .

  • The Small Interfering Rna Therapeutics market is set to add $5.6 billion between 2024 and 2034, with manufacturer targeting Drug Discovery & Development & Genetic Disorders Application projected to gain a larger market share.

  • With Advancements in rnai technology, and increasing Prevalence of Chronic Diseases, Small Interfering Rna Therapeutics market to expand 432% between 2024 and 2034.

small interfering rna therapeutics market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Small Interfering RNA Therapeutics - Country Share Analysis

Opportunities in the Small Interfering RNA Therapeutics

The Small Interfering RNA Therapeutics industry presents significant growth potential in untapped markets. The healthcare infrastructure of Asia and Africa is also expanding while genetic disorder awareness grows in these emerging economies. The unmet needs in these regions create an ideal opportunity for Small Interfering RNA Therapeutics to expand its market presence.

Growth Opportunities in North America and Asia-Pacific

The Small Interfering RNA Therapeutics market in North America demonstrates a substantial growth pattern. The market growth stems from the strong presence of biotechnology and pharmaceutical industries together with major investments in genomics and proteomics research. The region contains multiple prominent companies that focus on RNA therapeutics which creates an active competitive environment. The rising occurrence of chronic diseases and genetic disorders drives up the need for Small Interfering RNA Therapeutics. The market receives support from government backing through positive policies and funding for research and development activities.
The Asia-Pacific region stands as an emerging market for Small Interfering RNA Therapeutics. The market expansion in this region results from growing healthcare spending combined with rising patient understanding and better healthcare facilities. The growing number of cancer and diabetes cases in India and China drives the need for advanced treatments which in turn drives up the market demand for Small Interfering RNA Therapeutics. The Small Interfering RNA Therapeutics market benefits from growing partnerships between international and domestic companies which creates competitive market dynamics and new market possibilities.

Market Dynamics and Supply Chain

01

Driver: Advancements in RNAi Technology, and Rising Investments in Biopharmaceutical Research

The field of Small Interfering RNA Therapeutics is also experiencing rapid growth due to advancements in RNAi technology. This technology, which involves the use of small interfering RNAs to silence specific genes, is also being increasingly adopted in the development of novel therapeutics. These advancements are also expected to drive the growth of siRNA therapeutics, particularly in the treatment of genetic disorders and cancers where gene silencing can also play a crucial role.

The Small Interfering RNA Therapeutics market is also also being driven by the rising investments in biopharmaceutical research. These investments are also facilitating the development of innovative siRNA therapeutics and helping to accelerate their clinical trials.

The Small Interfering RNA Therapeutics market faces significant growth due to the rising occurrence of chronic diseases including cancer and diabetes and cardiovascular diseases. The therapeutic approach of siRNA works by targeting specific genes that are also dysregulated in these diseases thus offering a promising treatment solution. The market for siRNA therapeutics will also expand because patients need effective treatments for their chronic diseases.

02

Restraint: Regulatory Hurdles

Small Interfering RNA Therapeutics encounter major regulatory obstacles during their development and commercialization process. Health authorities across the world including the U. S. Food and Drug Administration and the European Medicines Agency enforce strict regulations on these therapeutics. The complete approval process which includes preclinical and clinical trials extends for multiple years while demanding significant financial investment. The lengthy approval process hinders market expansion and restricts these therapeutics from reaching patients who need them.

03

Opportunity: Strategic Collaborations for Accelerated Development and Technological Innovations Driving Growth

The Small Interfering RNA Therapeutics market will benefit from strategic collaborations between pharmaceutical companies, research institutions, and biotech firms. The development and commercialization of new therapeutics will be accelerated through these partnerships which will drive market growth. These collaborations will also facilitate knowledge exchange and resource sharing which will enhance the overall efficiency and effectiveness of the research and development process.

The fast progress of biotechnology has enabled scientists to create better Small Interfering RNA Therapeutics through improved efficiency and effectiveness. The market will experience significant growth because of recent innovations in RNA interference technology. The application of AI and ML in research and development will speed up the discovery of new therapeutic agents.

04

Challenge: Delivery Challenges

The successful application of Small Interfering RNA Therapeutics largely depends on efficient delivery systems. However, the development of such systems is a complex process, fraught with challenges such as ensuring stability, avoiding immune response, and achieving targeted delivery. These challenges can impede the progress of research and development in this field, thereby restraining the market growth.

Supply Chain Landscape

1

Raw Material Suppliers

Sigma-AldrichThermo Fisher Scientific
2

Production

Alnylam PharmaceuticalsDicerna Pharmaceuticals
3

Distribution & Logistics

FedExDHL
4

End Users

HospitalsResearch InstitutesBiopharmaceutical Companies
Small Interfering RNA Therapeutics - Supply Chain

Use Cases of Small Interfering RNA Therapeutics in Oncology & Viral Infections Management

Oncology Therapeutics : Small Interfering RNA Therapeutics, particularly those targeting specific oncogenes, have been widely used in the field of Oncology. They offer a unique advantage in selectively silencing genes that contribute to tumor growth, thereby inhibiting the progression of cancer. Top players in this field include Alnylam Pharmaceuticals and Dicerna Pharmaceuticals, both of which have a strong market position due to their innovative therapeutics and robust clinical pipelines.
Genetic Disorders Treatment : Small Interfering RNA Therapeutics are also employed in the treatment of genetic disorders. They are predominantly used to silence disease-causing genes, providing a novel approach to managing conditions that were previously untreatable. Ionis Pharmaceuticals and Alnylam Pharmaceuticals are leading the market in this application, with their strengths lying in their proprietary technologies and successful clinical trials.
Viral Infections Management : Another significant application of Small Interfering RNA Therapeutics is in the management of viral infections. These therapeutics can target and silence viral genes, preventing the replication of the virus and controlling the infection. Arrowhead Pharmaceuticals and Quark Pharmaceuticals are key market players in this application, recognized for their innovative RNA interference technologies and strong market presence.

Recent Developments

Recent market developments have significantly impacted the landscape of siRNA Therapeutics. The industry has seen a surge in research and development activities, primarily driven by the growing prevalence of genetic disorders and the need for effective therapeutic solutions. The advent of advanced technologies in the field of RNA interference has paved the way for the development of innovative siRNA therapeutics, thereby propelling the market growth.

December 2024 : Global biotech firm, Genzyme Therapeutics, launched its novel Small Interfering RNA Therapeutics for the treatment of Huntingtons disease, marking a significant milestone in neurodegenerative disorder treatment
October 2024 : RNAi Therapeutics Inc. announced a strategic partnership with MedTech Solutions to advance the development and commercialization of Small Interfering RNA Therapeutics in oncology
July 2024 : BioNex Solutions, a leading provider in the Small Interfering RNA Therapeutics market, secured FDA approval for its innovative siRNA-based drug for the treatment of rare genetic disorders.

Impact of Industry Transitions on the Small Interfering RNA Therapeutics Market

As a core segment of the Biotechnology industry, the Small Interfering RNA Therapeutics market develops in line with broader industry shifts. Over recent years, transitions such as Advancements in Drug Delivery Systems and Regulatory Approvals and Commercialization have redefined priorities across the Biotechnology sector, influencing how the Small Interfering RNA Therapeutics market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Advancements in Drug Delivery Systems

The Small Interfering RNA Therapeutics industry has experienced major developments in drug delivery systems. The advancements in drug delivery systems have made it possible to deliver Small Interfering RNA Therapeutics efficiently and precisely which improves their therapeutic effects. The creation of lipid nanoparticles has transformed the delivery of Small Interfering RNA Therapeutics by protecting them from degradation and improving their availability in the body. The transition has led to better patient results and has driven forward the development of pharmaceutical and biotechnology industries.

02

Regulatory Approvals and Commercialization

The Small Interfering RNA Therapeutics industry has experienced a major transition with regulatory approvals and commercialization of Small Interfering RNA Therapeutics. The FDA approval of Patisiran, the first-ever Small Interfering RNA Therapeutics, marked a significant milestone in the industry. This transition has not only validated the potential of Small Interfering RNA Therapeutics but has also opened up new opportunities for the pharmaceutical industry and has set a precedent for regulatory authorities worldwide.